2019
DOI: 10.1007/s11901-019-00456-2
|View full text |Cite
|
Sign up to set email alerts
|

The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

Abstract: Purpose of Review Biologics are well established in the treatment of many immuno-inflammatory diseases including inflammatory bowel disease (IBD). However, although primary sclerosing cholangitis (PSC) is closely associated with IBD, the role of biologics in PSC remains uncertain. Many new biologics are becoming available to treat IBD, and this review aims to use the experience of biologics in PSC so far to guide more effective evaluation of emerging therapies in the future. Recent … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
23
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 21 publications
(24 citation statements)
references
References 64 publications
0
23
0
1
Order By: Relevance
“…13 This hypothesis has not been tested in clinical trials, although a few observational studies published recently document the clinical experience of treating patients who have PSC and IBD with vedolizumab. 14 These cohorts are usually limited to a small number of centers, leading to a small sample size. We sought to contribute to this literature by documenting our experience in a larger international cohort of patients with PSC and IBD.…”
Section: Discussionmentioning
confidence: 99%
“…13 This hypothesis has not been tested in clinical trials, although a few observational studies published recently document the clinical experience of treating patients who have PSC and IBD with vedolizumab. 14 These cohorts are usually limited to a small number of centers, leading to a small sample size. We sought to contribute to this literature by documenting our experience in a larger international cohort of patients with PSC and IBD.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, the relationships between IBD and some of the top DEGs ( Figure 2B ), such as MMP1 ( Wang and Qiu, 2010 ) and COL12A1 ( Ji et al, 2020 ), have also been reported. Interestingly, the serum levels of LOXL2 are significantly higher in primary sclerosing cholangitis (PSC) ( Pollheimer et al, 2018 ), which is closely associated with IBD, and LOXL2 targeting in IBD has been evaluated in PSC ( Lynch et al, 2019 ). Meanwhile, among the top down-regulated DEGs, such as BRINP3 , CKB , CP , CLDN8 and DPP10-AS1 , down regulation of BRINP3 ( Smith et al, 2014 ), CLDN8 ( Wang et al, 2016 ), has been reported in UC.…”
Section: Resultsmentioning
confidence: 99%
“…Case series and observational cohorts have assessed anti-integrin therapies such as vedolizumab in PSC-IBD, with conflicting results (comprehensively summarised by Lynch et al[ 96 ]). Whilst some patients had a fall in ALP, others had a rise in ALP and ALT levels, independent of their endoscopic/histological colitis activity response[ 96 ]. None were stratified by sIgG4 level.…”
Section: Therapeutic Options For Psc and High Igg4 Levelsmentioning
confidence: 99%